Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

  • POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes
  • Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types
  • Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry

The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or enough actionable data about how tumors with specific mutations respond to drugs. One innovator in the cancer research space, Predictive Oncology Inc. (NASDAQ: POAI), is working to change this dynamic by bringing its cutting-edge, AI-driven predictive models of tumor drug response and outcome to cancer research. These models predict how tumors respond to drugs and can be used for both clinical decision support, i.e. individualizing a patient’s therapy as well as research into new therapies, in partnership with the pharmaceutical and biotech industries.

With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist determine a tailored therapy for that patient.

Helomics’ is building AI-driven predictive models by leveraging; a unique database of 150,000 tumor genomic and drug response profiles gathered from over 15 years of clinical testing using its TruTumor platform; access to over 15 years of outcome data from a national network of oncologists; plus a physical biobank of tumor samples that is being sequenced as part of its CancerQuest 2020 initiative (http://nnw.fm/i2VeT) to generate rich genomic profiles.

Along with subsidiaries TumorGenesis and Skyline Medical, POAI brings precision medicine to the treatment of cancer through collaborations with key players in the pharmaceutical, diagnostic and biotech industries. According to Mordor Intelligence Inc, oncology is expected to have the largest share of the precision medicine industry with estimated market dominance in excess of 30% over other precision medicine segments, and a CAGR of 10.3% from 2018 to 2024 (http://nnw.fm/16Uqq).

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050